Alzheimer's Disease Cooperative Study

ADCS的总体目标是推进对治疗、延迟或预防AD有用的干预措施的开发研究，特别是可能不是由行业开发的干预措施。特别是，ADCS“侧重于仪器和试验方法，以及对可能无法由制药业研究的潜在疗法的测试。在即将到来的赠款周期，ADCS将继续努力通过受控临床试验、开发新的仪器和试验设计、招募工作(特别关注少数族裔受试者的招募)来推动治疗学的发展。本组织将继续其最近对协作和数据共享的重视。具体目标：目标1：测试改善认知、减缓衰退速度或延迟/预防阿尔茨海默病的干预措施。这项申请中的四个项目中有三个旨在减缓疾病的进展。目的2：测试一种改善行为症状的干预措施。我们将扩展有希望的早期结果，支持一种肾上腺素能方法改善行为症状，进行一项多中心的哌唑嗪试验。目的3：设计用于临床试验的新仪器。在目前的周期中，我们已将仪器开发纳入我们最大的项目--A4试验。目的4：开发AD临床试验设计的新方法和创新方法。A4试验利用一种新的试验设计，在疾病的最早可行阶段，即临床前AD，测试领先的干预措施。目的5：开发AD临床试验分析的新方法和创新方法。生物统计学核心将继续努力推进AD试验设计的分析方法。将继续进行纵向数据优化建模的工作，包括连接不同数据集的新方法。目标6：扩大AD研究中研究的个体范围，包括高危个体和MCI患者。ADCS将其方法学研究的重点放在早期试验上，在这个周期中，两个最大的项目针对临床前AD和轻度认知障碍。目标7：加强将少数群体纳入AD研究。在接下来的周期中，ADCS少数民族招募核心将扩大外展工作，我们将要求站点在我们的两个最大的试验中达到少数民族招生目标。

The overall aim of the ADCS is to advance research in the development of interventions that might be useful for treating, delaying, or preventing AD, particularly interventions that might not be developed by industry. In particular, the ADCS "has focused on instrument and trial methodology, and the testing of potential therapeutics that might not otherwise be studied by the pharmaceutical industry. For the coming grant cycle, the ADCS will continue its efforts to advance therapeutics through controlled clinical trials, development o novel instruments and trial designs, recruitment efforts (with particular attention to recruitment f minority subjects). The organization will continue its recent emphasis on collaboration and data sharing. Specific Aims: Aim 1: Test interventions to Improve cognition, slow the rate of decline, or delay/prevent the onset of AD. Three of the four projects in this application aim to slow disease progression. Aim 2: Test an intervention to ameliorate behavioral symptoms. We will extend promising early results supporting an adrenergic approach amelioration of behavioral symptoms with a multicenter trial of prazosin. Aim 3: Design new instruments for use in clinical trials. For the present cycle, we have incorporated instrument development into our largest project, the A4 trial. Aim 4: Develop novel and innovative approaches to AD clinical trial design. The A4 trial utilizes a new trial design to test a leading intervention at the earliest feasible stge of disease, preclinical AD. Aim 5: Develop novel and innovative approaches to AD clinical trial analysis. The Biostatistics Core will continue efforts to advance analytical approaches to AD trial design. Work will continue on optimal modeling of longitudinal data, including novel methods to link diverse datasets. Aim 6:.Expand the range of individuals studied in AD studies to include at-risk individuals and those with MCI. The ADCS has focused its methodological research on early-stage trials, and for this cycle, the two largest projects target preclinical AD and mild cognitive impairment. Aim 7: Enhance the recruitment of minority groups into AD studies. For the coming cycle, the ADCS Minority Recruitment Core will expand outreach efforts, and we will require sites to meet minority enrollment targets in our two largest trials.